Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest Update

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was the target of a significant increase in short interest in February. As of February 15th, there was short interest totalling 333,800 shares, an increase of 243.1% from the January 31st total of 97,300 shares. Based on an average trading volume of 1,590,000 shares, the short-interest ratio is presently 0.2 days. Currently, 6.0% of the company’s stock are short sold.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. PFG Investments LLC bought a new stake in Tonix Pharmaceuticals in the fourth quarter worth $72,000. Two Sigma Investments LP bought a new stake in shares of Tonix Pharmaceuticals during the 4th quarter worth about $66,000. Northern Trust Corp acquired a new position in shares of Tonix Pharmaceuticals during the 4th quarter valued at about $162,000. Jane Street Group LLC raised its stake in shares of Tonix Pharmaceuticals by 5,932.3% in the 4th quarter. Jane Street Group LLC now owns 1,662,682 shares of the company’s stock valued at $548,000 after acquiring an additional 1,635,119 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new position in shares of Tonix Pharmaceuticals in the 4th quarter valued at approximately $526,000. Institutional investors and hedge funds own 82.26% of the company’s stock.

Tonix Pharmaceuticals Trading Down 3.9 %

NASDAQ:TNXP opened at $7.86 on Friday. The company has a market capitalization of $14.69 million, a P/E ratio of 0.00 and a beta of 2.07. The stock’s 50 day moving average price is $23.93 and its 200 day moving average price is $21.87. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. Tonix Pharmaceuticals has a 52 week low of $7.54 and a 52 week high of $1,244.16.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a research note on Monday, February 10th. They issued a “sell” rating on the stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.